CD8A and neoplasm: In vivo STAT3 activation enhances FAO and inhibits glycolysis in CD8+ T effector cells, impairs their effector function, and promotes tumor growth65, but in vitro STAT3 activation leads to a stronger antitumor ability in vivo because of T cell memory formation, which is crucial for long-term antitumor immune responses.